Biologic and systemic agents in dermatology / Paul S. Yamauchi, Editor
Written by leading experts in the field and designed for dermatologists and residents, this book includes evidence-based medicine that underscores the clinical data, as well as practical tips on how to use both biologic and systemic agents in the field of dermatology. In the past decade, there have been several groundbreaking advances in medical dermatology. Novel biologic and systemic agents have been developed to treat inflammatory disorders, including psoriasis and atopic dermatitis, as well as skin malignancies such as melanoma. Biologic and Systemic Agents in Dermatology encompasses these developments by describing the mechanism of action of these various agents and the clinical efficacy and safety to treating these respective disorders. The utilization of biologic and systemic agents in other dermatologic conditions, pharmacoeconomics, pharmacovigilance, and clinical trials outcomes are discussed as well as topics including tumor necrosis, conventional systemic agents for psoriatic disease, and oral agents for atopic dermatitis.
History of Therapies in Dermatology. Past to Present -- Validated scoring systems -- Interpreting Clinical Trial Data -- Compliance and Persistency -- Quality of Life in the Dermatology Practice -- Medical Legal Issues with Biologic Agents in the Treatment of Psoriasis -- Patient and Physician Perspectives on Traditional Systemic and Biologic Therapies for Psoriasis -- Outcomes of Comorbidities with Biologic and Systemic Agents -- Pharmacovigilance -- Pharmacoeconomics of Biologic Therapy in Dermatology -- Immunogenicity of Biologic Agents in Psoriasis -- Manufacturing of Biologics -- Tumor Necrosis Factor Inhibition -- Dual Inhibition of IL-12/IL- 23 and Selective Inhibition of IL-23 in Psoriasis.- Interleukin-17 Inhibition for the Treatment of Inflammatory Skin Disease -- Systemic Therapies in Psoriasis -- Nail, Scalp, and Palmoplantar Psoriasis -- Current and Emerging Treatments for Psoriatic Arthritis -- JAK Kinase Inhibitors in Dermatology -- Fumaric Acid Esters in Dermatology -- Phosphodiesterase Inhibitors for the Treatment of Inflammatory Skin Conditions -- Oral Retinoids in Dermatology -- Combination Therapy with Biologics and Other Systemic Treatments in Psoriasis -- Transitioning Biologic and Systemic Therapies in Psoriatic Patients -- Practical Considerations and Complex Cases in Psoriasis -- Biosimilars in Dermatology -- Biological Agents in Pediatric Dermatology -- Oral systemic Agents in Pediatric Dermatology -- Utilization of Biologic and Systemic Agents in the Elderly -- Miscellaneous Uses of Biologic and Systemic Agents in Other Dermatologic Conditions -- Biologics for the Treatment of Atopic Dermatitis -- Oral Agents for Atopic Dermatitis: Current and in Development -- Cutaneous T-cell lymphoma -- Anti-CD20 Agents and Potential Novel Biologics in Pemphigus Vulgaris and Other Autoimmune Blistering Diseases -- Oral Systemic Agents for Immunobullous Disorders -- Biologic and Systemic Agents in Hidradenitis Suppurativa -- Systemic and Biologic Agents for Lupus Erythematosus -- Anti-IgE Therapy in Dermatology -- Role of Intravenous Immunoglobulin in Dermatologic Disorders -- Systemic Antifungals -- Systemic Antivirals in Dermatology -- Antihelmintics in Dermatology -- Systemic Therapies for Scarring and Non-scarring alopecia -- Dapsone in Dermatology -- Systemic Non-Antibiotic Therapy in acne and rosacea -- Oral Antibiotics in Dermatology: A Practical Overview with Clinically Relevant Correlations and Management Suggestions -- Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma -- Update in Immunotherapies for Melanoma -- Patient advocacy organizations..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
[2018] |
|---|---|
| Erschienen: |
Cham, Switzerland: Springer ; 2018 |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamauchi, Paul S. [HerausgeberIn] |
|---|
| Links: |
|---|
| ISBN: |
|---|
| Nlm: |
QV 60 |
|---|---|
| Themen: |
Anti-Infective Agents |
| Umfang: |
1 Online-Ressource (XVII, 574 Seiten) ; Illustrationen |
|---|
| doi: |
10.1007/978-3-319-66884-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1659264014 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1659264014 | ||
| 003 | DE-627 | ||
| 005 | 20240323100936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180219s2018 gw |||||o 00| ||eng c | ||
| 020 | |a 9783319668840 |9 978-3-319-66884-0 | ||
| 024 | 7 | |a 10.1007/978-3-319-66884-0 |2 doi | |
| 035 | |a (DE-627)1659264014 | ||
| 035 | |a (DE-576)499973887 | ||
| 035 | |a (DE-599)BSZ499973887 | ||
| 035 | |a (OCoLC)1027007583 | ||
| 035 | |a (DE-He213)978-3-319-66884-0 | ||
| 035 | |a (EBP)040792889 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XA-DE | ||
| 050 | 0 | |a RL1-803 | |
| 060 | 0 | |a QV 60 | |
| 072 | 7 | |a MJK |2 bicssc | |
| 072 | 7 | |a MED017000 |2 bisacsh | |
| 245 | 1 | 0 | |a Biologic and systemic agents in dermatology |c Paul S. Yamauchi, Editor |
| 264 | 1 | |a Cham, Switzerland |b Springer |c [2018] | |
| 300 | |a 1 Online-Ressource (XVII, 574 Seiten) |b Illustrationen | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a SpringerLink |a Bücher | |
| 490 | 0 | |a Springer eBook Collection |a Medicine | |
| 520 | |a Written by leading experts in the field and designed for dermatologists and residents, this book includes evidence-based medicine that underscores the clinical data, as well as practical tips on how to use both biologic and systemic agents in the field of dermatology. In the past decade, there have been several groundbreaking advances in medical dermatology. Novel biologic and systemic agents have been developed to treat inflammatory disorders, including psoriasis and atopic dermatitis, as well as skin malignancies such as melanoma. Biologic and Systemic Agents in Dermatology encompasses these developments by describing the mechanism of action of these various agents and the clinical efficacy and safety to treating these respective disorders. The utilization of biologic and systemic agents in other dermatologic conditions, pharmacoeconomics, pharmacovigilance, and clinical trials outcomes are discussed as well as topics including tumor necrosis, conventional systemic agents for psoriatic disease, and oral agents for atopic dermatitis | ||
| 520 | |a History of Therapies in Dermatology. Past to Present -- Validated scoring systems -- Interpreting Clinical Trial Data -- Compliance and Persistency -- Quality of Life in the Dermatology Practice -- Medical Legal Issues with Biologic Agents in the Treatment of Psoriasis -- Patient and Physician Perspectives on Traditional Systemic and Biologic Therapies for Psoriasis -- Outcomes of Comorbidities with Biologic and Systemic Agents -- Pharmacovigilance -- Pharmacoeconomics of Biologic Therapy in Dermatology -- Immunogenicity of Biologic Agents in Psoriasis -- Manufacturing of Biologics -- Tumor Necrosis Factor Inhibition -- Dual Inhibition of IL-12/IL- 23 and Selective Inhibition of IL-23 in Psoriasis.- Interleukin-17 Inhibition for the Treatment of Inflammatory Skin Disease -- Systemic Therapies in Psoriasis -- Nail, Scalp, and Palmoplantar Psoriasis -- Current and Emerging Treatments for Psoriatic Arthritis -- JAK Kinase Inhibitors in Dermatology -- Fumaric Acid Esters in Dermatology -- Phosphodiesterase Inhibitors for the Treatment of Inflammatory Skin Conditions -- Oral Retinoids in Dermatology -- Combination Therapy with Biologics and Other Systemic Treatments in Psoriasis -- Transitioning Biologic and Systemic Therapies in Psoriatic Patients -- Practical Considerations and Complex Cases in Psoriasis -- Biosimilars in Dermatology -- Biological Agents in Pediatric Dermatology -- Oral systemic Agents in Pediatric Dermatology -- Utilization of Biologic and Systemic Agents in the Elderly -- Miscellaneous Uses of Biologic and Systemic Agents in Other Dermatologic Conditions -- Biologics for the Treatment of Atopic Dermatitis -- Oral Agents for Atopic Dermatitis: Current and in Development -- Cutaneous T-cell lymphoma -- Anti-CD20 Agents and Potential Novel Biologics in Pemphigus Vulgaris and Other Autoimmune Blistering Diseases -- Oral Systemic Agents for Immunobullous Disorders -- Biologic and Systemic Agents in Hidradenitis Suppurativa -- Systemic and Biologic Agents for Lupus Erythematosus -- Anti-IgE Therapy in Dermatology -- Role of Intravenous Immunoglobulin in Dermatologic Disorders -- Systemic Antifungals -- Systemic Antivirals in Dermatology -- Antihelmintics in Dermatology -- Systemic Therapies for Scarring and Non-scarring alopecia -- Dapsone in Dermatology -- Systemic Non-Antibiotic Therapy in acne and rosacea -- Oral Antibiotics in Dermatology: A Practical Overview with Clinically Relevant Correlations and Management Suggestions -- Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma -- Update in Immunotherapies for Melanoma -- Patient advocacy organizations. | ||
| 650 | 0 | |a Medicine | |
| 650 | 0 | |a Medicine & Public Health | |
| 650 | 0 | |a Dermatology | |
| 650 | 2 | |a Dermatologic Agents |x therapeutic use | |
| 650 | 2 | |a Skin Diseases |x drug therapy | |
| 650 | 2 | |a Biological Products |x therapeutic use | |
| 650 | 2 | |a Biological Factors |x therapeutic use | |
| 650 | 2 | |a Anti-Infective Agents |x therapeutic use | |
| 700 | 1 | |a Yamauchi, Paul S. |e herausgeberin |4 edt | |
| 776 | 1 | |z 9783319668833 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 978-3-319-66883-3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-3-319-66884-0 |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-319-66884-0 |m B:SPRINGER |x Verlag |z lizenzpflichtig |3 Volltext |
| 889 | |w (DE-627)1012124622 | ||
| 912 | |a ZDB-2-SEB | ||
| 912 | |a ZDB-2-SME |b 2018 | ||
| 912 | |a ZDB-2-SXM |b 2018 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a ISIL_DE-3 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a ISIL_DE-Ma9 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a ISIL_DE-Ma14 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a ISIL_DE-715 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a ISIL_DE-14 | ||
| 912 | |a GBV_ILN_2017 | ||
| 912 | |a ISIL_DE-576 | ||
| 951 | |a BO | ||
| 953 | |2 045F |a 616.5 | ||
| 980 | |2 22 |1 01 |x 0018 |b 1747786020 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |k Campuslizenz Universität Hamburg. - Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y zi06404 |z 05-02-18 | ||
| 980 | |2 65 |1 01 |x 0003/5555 |b 1831179326 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |c 03 |f --%%-- |d ebook |e --%%-- |j --%%-- |h OLR-SEB-ZDB-2-SME |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Die Weitergabe an Dritte sowie systematisches Downloaden sind untersagt. |y k3o |z 08-12-18 | ||
| 980 | |2 100 |1 01 |x 3100 |b 1845781171 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |c 09 |f --%%-- |d eBook Springer |e --%%-- |j --%%-- |h OLR-SEB |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y z |z 28-01-19 | ||
| 980 | |2 101 |1 01 |x 3101 |b 1845874684 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |c 09 |f --%%-- |d eBook Springer |e --%%-- |j --%%-- |h OLR-SEB |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y z |z 28-01-19 | ||
| 980 | |2 120 |1 01 |x 0715 |b 1748062662 |h OLR-ESP |k Campusweiter Zugriff (Universität Oldenburg). - Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden. |y z |z 05-02-18 | ||
| 980 | |2 120 |1 02 |x 0715 |b 3936788073 |c 00 |f --%%-- |d --%%-- |e g |j --%%-- |h alma |k ww |y z |z 11-06-21 | ||
| 980 | |2 2006 |1 01 |x DE-14 |b 340848919X |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 02-01-18 | ||
| 980 | |2 2017 |1 01 |x DE-576 |b 340848922X |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Besitznachweis BSZ nur für Dateneinspielung, keine echte Lizenz vorhanden |y l01 |z 02-01-18 | ||
| 981 | |2 22 |1 01 |x 0018 |y Volltextzugang |r http://dx.doi.org/10.1007/978-3-319-66884-0 | ||
| 981 | |2 22 |1 01 |x 0018 |y Nur für Angehörige der Universität Hamburg: Volltextzugang von außerhalb des Campus |r http://emedien.sub.uni-hamburg.de/han/SpringerEbooksUKE/dx.doi.org/10.1007/978-3-319-66884-0 | ||
| 981 | |2 65 |1 01 |x 0003/5555 |y Volltextzugang Campus |r http://dx.doi.org/10.1007/978-3-319-66884-0 | ||
| 981 | |2 100 |1 01 |x 3100 |r http://dx.doi.org/10.1007/978-3-319-66884-0 | ||
| 981 | |2 100 |1 01 |x 3100 |y für Uniangehörige: Zugang weltweit |r https://han.med.uni-magdeburg.de/han/SPR-eBook-Medicine-einzeln/dx.doi.org/10.1007/978-3-319-66884-0 | ||
| 981 | |2 101 |1 01 |x 3101 |r http://dx.doi.org/10.1007/978-3-319-66884-0 | ||
| 981 | |2 101 |1 01 |x 3101 |y für Uniangehörige: Zugang weltweit |r https://han.med.uni-magdeburg.de/han/SPR-eBook-Medicine-einzeln/dx.doi.org/10.1007/978-3-319-66884-0 | ||
| 981 | |2 120 |1 01 |x 0715 |r http://dx.doi.org/10.1007/978-3-319-66884-0 | ||
| 981 | |2 120 |1 02 |x 0715 |r http://49gbv-uob-primo.hosted.exlibrisgroup.com/openurl/49GBV_UOB/UOB_services_page?u.ignore_date_coverage=true&rft.mms_id=991015272477303501 | ||
| 981 | |2 2006 |1 01 |x DE-14 |r http://dx.doi.org/10.1007/978-3-319-66884-0 | ||
| 983 | |2 120 |1 00 |x DE-715 |8 99 |a ww | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 120 |1 01 |x 0715 |a YH 2021 | ||
| 995 | |2 65 |1 01 |x 0003/5555 |a OLR-SEB-ZDB-2-SME | ||
| 995 | |2 100 |1 01 |x 3100 |a OLR-SEB | ||
| 995 | |2 101 |1 01 |x 3101 |a OLR-SEB | ||
| 995 | |2 120 |1 01 |x 0715 |a OLR-ESP | ||
| 995 | |2 120 |1 02 |x 0715 |a alma | ||